Article
Two susceptibility loci identified for prostate cancer aggressiveness.
Nature communications - 5 May 2015
Berndt Sonja I, Wang Zhaoming, Yeager Meredith, Alavanja Michael C, Albanes Demetrius, Amundadottir Laufey, Andriole Gerald, Beane Freeman Laura, Campa Daniele, Cancel-Tassin Geraldine, Canzian Federico, Cornu Jean-Nicolas, Cussenot Olivier, Diver W Ryan, Gapstur Susan M, Grönberg Henrik, Haiman Christopher A, Henderson Brian, Hutchinson Amy, Hunter David J, Key Timothy J, Kolb Suzanne, Koutros Stella, Kraft Peter, Le Marchand Loic, Lindström Sara, Machiela Mitchell J, Ostrander Elaine A, Riboli Elio, Schumacher Fred, Siddiq Afshan, Stanford Janet L, Stevens Victoria L, Travis Ruth C, Tsilidis Konstantinos K, Virtamo Jarmo, Weinstein Stephanie, Wilkund Fredrik, Xu Jianfeng, Lilly Zheng S, Yu Kai, Wheeler William, Zhang Han, Sampson Joshua, Black Amanda, Jacobs Kevin, Hoover Robert N, Tucker Margaret, Chanock Stephen J
Abstract excerpt
Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.